Efficient Vpu-mediated tetherin antagonism by an HIV-1 group O strain

Journal of Virology

Volumn 91, Issue 6, 2017, Pages

  Mack, Katharina ^a   Starz, Kathrin ^a   Sauter, Daniel ^a   Langer, Simon ^a   Bibollet Ruche, Frederic ^b   Learn, Gerald H ^b   Stürzel, Christina M ^a   Leoz, Marie ^c,d   Plantier, Jean Christophe ^c,d   Geyer, Matthias ^e   Hahn, Beatrice H ^b   Kirchhoff, Frank ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HÔPITAL CHARLES NICOLLE   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Antagonism; HIV 1 group O; Tetherin; Vpu

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; NEF PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VPU PROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP M; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP O; MOLECULAR CLONING; NONHUMAN; PHYLOGENY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; VIRUS CHARACTERIZATION; VIRUS IDENTIFICATION; VIRUS RELEASE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANTAGONISTS AND INHIBITORS; CELL LINE; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; GPI-LINKED PROTEINS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; NF-KAPPA B; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS RELEASE;

EID: 85014109948     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02177-16     Document Type: Article

References (86)

1. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JFY, Sharp PM, Shaw GM, Peeters M, Hahn BH. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-526. https://doi.org/10.1126/science.1126531.
2. D'arc M, Ayouba A, Esteban A, Learn GH, Boué V, Liegeois F, Etienne L, Tagg N, Leendertz FH, Boesch C, Madinda NF, Robbins MM, Gray M, Cournil A, Ooms M, Letko M, Simon VA, Sharp PM, Hahn BH, Delaporte E, Mpoudi Ngole E, Peeters M. 2015. Origin of the HIV-1 group O epidemic in western lowland gorillas. Proc Natl Acad Sci U S A 112: E1343-E1352. https://doi.org/10.1073/pnas.1502022112.
3. Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou T. 2008. Primate lentivirus capsid sensitivity to TRIM5 proteins. J Virol 82:6772-6777. https://doi.org/10.1128/JVI.00410-08.
4. Stremlau M, Owens CM, Perron MJ. 2004. The cytoplasmic body component TRIM5+ restricts HIV-1 infection in Old World monkeys. Nature 427.
5. Sawyer SL, Wu LI, Emerman M, Malik HS. 2005. Positive selection of primate TRIM5 alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A 102:2832-2837. https://doi.org/10.1073/pnas.0409853102.
6. Stremlau M, Perron M, Welikala S, Sodroski J. 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5 alpha determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139-3145. https://doi.org/10.1128/JVI.79.5.3139-3145.2005.
7. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH. 2004. Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol 78:12041-12046. https://doi.org/10.1128/JVI.78.21.12041-12046.2004.
8. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. https://doi.org/10.1038/nature00939.
9. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. https://doi.org/10.1016/S0092-8674(03)00423-9.
10. Mangeat B, Turelli P, Caron G, Friedli M. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103. https://doi.org/10.1038/nature01709.
11. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. https://doi.org/10.1038/nature 01707.
12. Delaugerre C, De Oliveira F, Lascoux-Combe C, Plantier JC, Simon F. 2011. HIV-1 group N: travelling beyond Cameroon. Lancet 378:1894. https://doi.org/10.1016/S0140-6736(11)61457-8.
13. Mourez T, Simon F, Plantier J-C. 2013. Non-M variants of human immunodeficiency virus type 1. Clin Microbiol Rev 26:448-461. https://doi.org/10.1128/CMR.00012-13.
14. Plantier J-CC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F. 2009. A new human immunodeficiency virus derived from gorillas. Nat Med 15:871-872. https://doi.org/10.1038/nm.2016.
15. Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, Mbanya D, Kaptué L, Ndembi N, Gürtler L, Devare S, Brennan CA. 2011. Confirmation of putative HIV-1 group P in Cameroon. J Virol 85: 1403-1407. https://doi.org/10.1128/JVI.02005-10.
16. Sauter D, Specht A, Kirchhoff F. 2010. Tetherin: holding on and letting go. Cell 141:392-398. https://doi.org/10.1016/j.cell.2010.04.022.
17. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS epidemic. Cold Spring Harb Perspect Med 5:1-23.
18. Neil SJD, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. https://doi.org/10.1038/nature06553.
19. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. https://doi.org/10.1016/j.chom.2008.03.001.
20. Perez-Caballero D, Zang T, Ebrahimi A, Mcnatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511. https://doi.org/10.1016/j.cell.2009.08.039.
21. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. 2003. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709. https://doi.org/10.1034/j.1600-0854.2003.00129.x.
22. Liberatore RA, Bieniasz PD. 2011. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A 108:18097-18101. https://doi.org/10.1073/pnas.1113694108.
23. Dave VP, Hajjar F, Dieng MM, Haddad é, Cohen éA. 2013. Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology 10:128. https://doi.org/10.1186/1742-4690-10-128.
24. Ikeda H, Nakaoka S, de Boer RJ, Morita S, Misawa N, Koyanagi Y. 2016. Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model. Retrovirology 13:23. https://doi.org/10.1186/s12977-016-0252-2.
25. Kmiec D, Iyer SS, Stürzel CM, Sauter D, Hahn BH, Kirchhoff F. 2016. Vpumediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance. mBio 7:e00934-16. https://doi.org/10.1128/mBio.00934-16.
26. Sauter D, Vogl M, Kirchhoff F. 2011. Ancient origin of a deletion in human BST2/tetherin that confers protection against viral zoonoses. Hum Mutat 32:1243-1245. https://doi.org/10.1002/humu.21571.
27. Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421. https://doi.org/10.1016/j.chom.2009.10.004.
28. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana Ben I, Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5:e1000429. https://doi.org/10.1371/journal.ppat.1000429.
29. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67. https://doi.org/10.1016/j.chom.2009.05.008.
30. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, Learn GH, Bibollet-Ruche F, Fritz JV, Fackler OT, Hahn BH, Kirchhoff F. 2012. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 8:e1003093. https://doi.org/10.1371/journal.ppat.1003093.
31. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. 2010. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13. https://doi.org/10.1186/1742-4690-7-13.
32. Sauter D, Hué S, Petit SJ, Plantier J-C, Towers GJ, Kirchhoff F, Gupta RK. 2011. HIV-1 group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 8:103. https://doi.org/10.1186/1742-4690-8-103.
33. Petit SJ, Blondeau C, Towers GJ. 2011. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J Gen Virol 92:2937-2948. https://doi.org/10.1099/vir.0.035931-0.
34. Vigan R, Neil SJD. 2011. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol 85:9737-9748. https://doi.org/10.1128/JVI.00479-11.
35. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. 2011. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8:78. https://doi.org/10.1186/1742-4690-8-78.
36. Kluge SF, Mack K, Iyer SS, Pujol M, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, Bibollet-Ruche F, Plenderleith LJ, Peeters M, Geyer M, Sharp PM, Fackler OT, Hahn BH, Kirchhoff F. 2014. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe 16:639-650. https://doi.org/10.1016/j.chom.2014.10.002.
37. Berg MG, Yamaguchi J, Alessandri-Gradt E, Tell RW, Plantier J-C, Brennan CA. 2016. A pan-HIV strategy for complete genome sequencing. J Clin Microbiol 54:868-882. https://doi.org/10.1128/JCM.02479-15.
38. Peeters M, Liegeois F, Torimiro N, Bourgeois A, Mpoudi E, Vergne L, Saman E, Delaporte E, Saragosti S. 1999. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol 73:7368-7375.
39. Ngoupo PA, Sadeuh-Mba SA, De Oliveira F, Ngono V, Ngono L, Tchend-jou P, Penlap V, Mourez T, Njouom R, Kfutwah A, Plantier J-C. 2016. First evidence of transmission of an HIV-1 M/O intergroup recombinant virus. AIDS 30:1-8.
40. Takehisa J, Zekeng L, Ido E, Yamaguchi-Kabata Y, Mboudjeka I, Harada Y, Miura T, Kaptu L, Hayami M. 1999. Human immunodeficiency virus type 1 intergroup (M/O) recombination in Cameroon. J Virol 73:6810-6820.
41. Sauter D, Hotter D, Van Driessche B, Stürzel CM, Kluge SF, Wildum S, Yu H, Baumann B, Wirth T, Plantier JC, Leoz M, Hahn BH, Van Lint C, Kirchhoff F. 2015. Differential regulation of NF-kB-mediated proviral and antiviral host gene expression by primate lentiviral nef and vpu proteins. Cell Rep 10:586-600. https://doi.org/10.1016/j.celrep.2014.12.047.
42. Cocka LJ, Bates P. 2012. Identification of alternatively translated tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 8:e1002931. https://doi.org/10.1371/journal.ppat.1002931.
43. Galão RP, Le Tortorec A, Pickering S, Kueck T, Neil SJD. 2012. Innate sensing of HIV-1 assembly by tetherin induces N-kB-dependent proinflammatory responses. Cell Host Microbe 12:633-644. https://doi.org/10.1016/j.chom.2012.10.007.
44. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. 2013. Stimulation of NF-κB activity by the HIV restriction factor BST2. J Virol 87:2046-2057. https://doi.org/10.1128/JVI.02272-12.
45. Akari H, Bour S, Kao S, Adachi A, Strebel K. 2001. The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor κB-dependent expression of antiapoptotic factors. J Exp Med 194:12991312.
46. Bour S, Perrin C, Akari H, Strebel K. 2001. The human immunodeficiency virus type 1 Vpu protein inhibits NF-κB activation by interfering with βTrCP-mediated degradation of IκB. J Biol Chem 276:15920-15928. https://doi.org/10.1074/jbc.M010533200.
47. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. 2007. Clathrinmediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 120:3850-3858. https://doi.org/10.1242/jcs.003343.
48. Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J, Tanaka Y. 2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with α-adaptin. J Biol Chem 284:15927-15941. https://doi.org/10.1074/jbc.M109.005124.
49. Weinelt J, Neil SJD. 2014. Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. J Virol 88:5845-5858. https://doi.org/10.1128/JVI.03818-13.
50. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana Ben I, Johnson WE, Neil SJD, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5:e1000300.
51. Kobayashi T, Ode H, Yoshida T, Sato K, Gee P, Yamamoto SP, Ebina H, Strebel K, Sato H, Koyanagi Y. 2011. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol 85:932-945. https://doi.org/10.1128/JVI.01668-10.
52. McNatt MW, Zang T, Bieniasz PD. 2013. Vpu Binds Directly to Tetherin and Displaces It from Nascent Virions. PLoS Pathog 9:e1003299.
53. Kluge SF, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, Hahn BH, Kirchhoff F. 2013. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function. Retrovirology 10:32. https://doi.org/10.1186/1742-4690-10-32.
54. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 106:2868-2873. https://doi.org/10.1073/pnas.0813223106.
55. Dubé M, Bego MG, Paquay C, Cohen éA. 2010. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 7:114. https://doi.org/10.1186/1742-4690-7-114.
56. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT. 2010. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 84:4089-4094. https://doi.org/10.1128/JVI.01549-09.
57. Tervo H-M, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT. 2011. β-TrCP is dispensable for Vpu's ability to overcome the CD317/tetherinimposed restriction to HIV-1 release. Retrovirology 8:9. https://doi.org/10.1186/1742-4690-8-9.
58. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. 1998. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1:565-574. https://doi.org/10.1016/S1097-2765(00)80056-8.
59. Soucy TA, Smith PG, Rolfe M. 2009. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 15:3912-3916. https://doi.org/10.1158/1078-0432.CCR-09-0343.
60. Ramirez PW, Beatriz A, Silva D, Szaniawski M, Barker E, Bosque A. 2015. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins. Retrovirology 12:65. https://doi.org/10.1186/s12977-015-0192-2.
61. Stumptner-Cuvelette P, Morchoisne S, Dugast M, Le Gall S, Raposo G, Schwartz O, Benaroch P. 2001. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc Natl Acad Sci U S A 98: 12144-12149. https://doi.org/10.1073/pnas.221256498.
62. Schindler M, Würfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, Brenner M, Münch J, Kirchhoff F. 2003. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 77:10548-10556. https://doi.org/10.1128/JVI.77.19.10548-10556.2003.
63. Hussain A, Wesley C, Khalid M, Chaudhry A, Jameel S. 2008. Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol 82:893-902. https://doi.org/10.1128/JVI.01373-07.
64. Götz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigele A, Geyer M, Bibollet-Ruche F, Learn GH, Fackler OT, Hahn BH, Kirchhoff F. 2012. Reacquisition of nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12:373-380. https://doi.org/10.1016/j.chom.2012.07.008.
65. Goffinet C, Allespach I, Homann S, Tervo H, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-locker J, Fackler OT, Keppler OT, Banting G, Kra H. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297. https://doi.org/10.1016/j.chom.2009.01.009.
66. Bego MG, Côté é, Aschman N, Mercier J, Weissenhorn W, Cohen éA. 2015. Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells. PLoS Pathog 11:e1005024. https://doi.org/10.1371/journal.ppat.1005024.
67. Bego MG, Cong L, Mack K, Kirchhoff F. 31 August 2016. Differential control of BST2 restriction and plasmacytoid dendritic cell antiviral response by antagonists encoded by HIV-1 group M and O strains. J Virol https://doi.org/10.1128/JVI.01131-16.
68. Arias JF, Colomer-Lluch M, von Bredow B, Greene JM, MacDonald J, O'Connor DH, Serra-Moreno R, Evans DT. 21 September 2016. Tetherin antagonism by HIV-1 group M Nef proteins. J Virol https://doi.org/10.1128/JVI.01465-16.
69. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. 1994. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864. https://doi.org/10.1016/0092-8674(94)90360-3.
70. Rhee SS, Marsh JW. 1994. Human immunodeficiency virus type 1 Nefinduced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol 68:5156-5163.
71. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66:7193-7200.
72. Kasper MR, Collins KL. 2003. Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol 77:3041-3049. https://doi.org/10.1128/JVI.77.5.3041-3049.2003.
73. Kasper MR, Roeth JF, Williams M, Filzen TM, Fleis RI, Collins KL. 2005. HIV-1 Nef disrupts antigen presentation early in the secretory pathway. J Biol Chem 280:12840-12848. https://doi.org/10.1074/jbc.M413538200.
74. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. 2006. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125:1055-1067. https://doi.org/10.1016/j.cell.2006.04.033.
75. Larkin MA, Blackshields G, Brown NP, Chenna R, Mcgettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948. https://doi.org/10.1093/bioinformatics/btm404.
76. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307-321. https://doi.org/10.1093/sysbio/syq010.
77. Darriba D, Taboada GL, Doallo R, Posada D. 2012. jModelTest 2: more models, new heuristics and parallel computing. Nat Methods 9:772. https://doi.org/10.1038/nmeth.2109.
78. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC. 1999. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73:152-160.
79. Fouchier RAM, Meyer BE, Simon JHM, Fischer U, Malim MH. 1997. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 16:4531-4539. https://doi.org/10.1093/emboj/16.15.4531.
80. Münch J, Rajan D, Schindler M, Specht A, Ru E, Novembre FJ, Nerrienet E, Mu MC, Peeters M, Hahn BH, Kirchhoff F. 2007. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 81:13852-13864. https://doi.org/10.1128/JVI.00904-07.
81. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
82. Langer SM, Hopfensperger K, Iyer SS, Kreider EF, Learn H, Lee L, Hahn BH, Sauter D. 2015. A naturally occurring rev1-vpu fusion gene does not confer a fitness advantage to HIV-1. PLoS One 10:e0142118. https://doi.org/10.1371/journal.pone.0142118.
83. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Stürzel CM, Mack K, Reith E, Engelhart S, Ciuffi A, Hornung V, Sauter D, Telenti A, Kirchhoff F. 2016. Guanylate binding protein (GBP) 5 is an interferoninducible inhibitor of HIV-1 infectivity. Cell Host Microbe 19:504-514. https://doi.org/10.1016/j.chom.2016.02.019.
84. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T. 2009. Protein structure homology modelling using SWISS-MODEL workspace. Nat Protoc 4:1-13.
85. Zhang H, Lin EC, Das BB, Tian Y, Opella SJ. 2015. Structural determination of virus protein U from HIV-1 by NMR in membrane environments. BiochimBiophysActa1848:3007-3018.https://doi.org/10.1016/j.bbamem.2015.09.008.
86. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J. 2012. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287:58-67. https://doi.org/10.1074/jbc.M111.296772.